Verapamil Does Not Prolong the QT Interval, While Ibogaine Causes Marked QT Prolongation
Verapamil actually shortens the QT interval rather than prolonging it, whereas ibogaine causes significant QT prolongation (up to 647 ms reported) with associated life-threatening ventricular arrhythmias including torsades de pointes.
Verapamil's Effect on QT Interval
Verapamil is a calcium channel blocker that does not prolong the QT interval. The FDA drug label explicitly states that verapamil "prolongs the effective refractory period within the AV node" but makes no mention of QT prolongation 11. In fact, research demonstrates that verapamil shortens the QT interval, particularly at low heart rates during the diurnal period 2.
Key Evidence on Verapamil:
- Protective against QT prolongation: Verapamil is actually used therapeutically to prevent drug-induced torsades de pointes in acquired long QT syndrome models 3
- In experimental models of acquired LQTS, verapamil (0.1-5.0 μmol/L) dose-dependently abbreviated action potential duration, significantly decreased the QT interval, and suppressed early afterdepolarizations and torsades de pointes 3
- Guidelines note that verapamil is contraindicated with dofetilide (a known QT-prolonging drug), but this is to avoid drug interactions, not because verapamil itself prolongs QT 455
Ibogaine's Effect on QT Interval
In stark contrast, ibogaine causes severe QT prolongation with documented fatal consequences:
Magnitude of QT Prolongation:
- Maximum QTc of 647 ms documented in a case report, with QTc prolongation persisting for 12 days after ingestion 6
- Multiple case reports document QTc prolongation >500 ms with associated torsades de pointes 678
- A randomized crossover trial in 27 opioid-dependent patients showed dose-dependent QTc prolongation with noribogaine (ibogaine's active metabolite) at doses of 60-180 mg 9
Clinical Significance:
- Ibogaine is listed as a definite cause of torsades de pointes at crediblemeds.org 10
- Fatalities have occurred from ventricular arrhythmias, including torsades de pointes, even at therapeutic doses and in individuals without pre-existing cardiac conditions 78
- The cardiotoxic effects are primarily mediated by noribogaine (the metabolite), which has a much longer half-life than the parent compound, explaining prolonged QTc effects days after ibogaine clearance 6
Clinical Implications
The comparison is not between two QT-prolonging drugs, but between a drug that shortens QT (verapamil) and one that dangerously prolongs it (ibogaine).
For Verapamil:
- Can be used safely in patients requiring rate control for supraventricular arrhythmias 41111
- No routine QT monitoring required specifically for verapamil
- Primary concerns are hypotension, bradycardia, and negative inotropy—not QT prolongation
For Ibogaine:
- Requires continuous cardiac monitoring with baseline and serial ECGs 79
- Should only be used under controlled medical supervision with immediate defibrillation capability 8
- Consider CYP2D6 genotyping, as genetic variability in metabolism may contribute to higher cardiovascular risk 7
- QTc monitoring should continue for at least 12 days post-ingestion due to long-acting metabolite effects 6
Critical Pitfall:
Do not assume all cardiac medications affect QT similarly. Verapamil's calcium channel blocking mechanism actually provides protection against QT prolongation, while ibogaine's multiple receptor effects (including hERG channel blockade) cause dangerous QT prolongation with a narrow therapeutic margin and documented fatalities.